Prevalence of human T-cell lymphotropic virus (HTLV-1/2) in individuals from public health centers in Mozambique.
The prevalence of human T-cell lymphotropic viruses types 1 and 2 (HTLV-1/2) in Mozambique is not known. The present study examined blood samples from 208, 226, and 318 individuals from Northern, Central, and Southern Mozambique, respectively, of all socioeconomic and demographic strata attending public health centers in Mozambique for HTLV-1/2-specific antibodies. Serum samples were assessed for HIV- and HTLV-1/2-specific antibodies by using enzyme immunoassays, and infections with HTLV-1 and -2 were confirmed by using Western blot. An overall HTLV-1/2 prevalence of 2.3% (2.9% in female and 1.1% in male subjects) was observed, and the prevalence of infection increased with age. Regional variation in the prevalence of HIV and HTLV-1/2 was observed; 32.2%, 65.5%, and 44% of individuals tested HIV positive in Northern, Central, and Southern Mozambique, respectively, and 2.4%, 3.9%, and 0.9% tested HTLV-1/2 positive in the same regions. HTLV-1 infection was confirmed in these individuals. No association between HTLV-1 infection and sociodemographic variables or HIV status was detected, although the low number of HTLV-1-positive cases did not allow robust statistical analyses. The results obtained suggest different risk factors and epidemiologic correlates of HIV and HTLV-1 transmission in Mozambique. Furthermore, our results suggested that North and Central Mozambique should be considered endemic regions for HTLV-1 infection. As no cases of HTLV-2 were detected, HTLV-2 appears to have not been introduced into Mozambique.
Caterino-de-Araujo
Adele
A
Immunology Department, Adolfo Lutz Institute, Secretary of Health of São Paulo, São Paulo, S.P., Brazil. caterino@usp.br
Magri
Mariana Cavalheiro
MC
Costa
Emanuela Avelar Silva
EA
Manuel
Rolanda Carmen Rafael
RC
D000293:Adolescent; D000328:Adult; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data*; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D015490:HTLV-I Infections / Q000453:epidemiology* / Q000821:virology; D015491:HTLV-II Infections / Q000453:epidemiology* / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D015367:Human T-lymphotropic virus 2 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009073:Mozambique / Q000453:epidemiology; D015995:Prevalence; D011634:Public Health; D012307:Risk Factors; D055815:Young Adult
D000914:Antibodies, Viral